Program
Istaroxime
Also written as “istaroxime”.
Its studies are mostly in Heart Failure · Shock, Cardiogenic, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Windtree Therapeutics | 31 open or running | phase 2since Jul 9, 2015 | Jul 9, 2015 | none ahead |
| Debiopharm | 20 open or running | phase 2since Feb 5, 2009 | Feb 5, 2009 | none ahead |
| Lee's Pharmaceutical | 10 open or running | phase 1since Jun 17, 2015 | Jun 17, 2015 | none ahead |
| Seismic Pharmaceuticals Operations | 11 open or running | phase 3since May 1, 2026 | May 1, 2026 | Dec 2028phase 3 · NCT07583446 |
| sigma-tau i.f.r. | 10 open or running | phase 2since Feb 5, 2008 | Feb 5, 2008 | none ahead |
Also a collaborator on its studies: cvie-therapeutics-co-ltd, momentum-research-inc and mds-pharma-services.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 5, 2008First study: phase 2 study in Heart FailureNew to sigma-tau i.f.r.sigma-tau i.f.r. · NCT00616161 · 120 enrolled
- Feb 5, 2009Debiopharm's first study: phase 2 study in Heart FailureNew to DebiopharmDebiopharm · NCT00838253
- Mar 24, 2009Phase 1 study in Heart FailureDebiopharm · NCT00869115
- Jun 17, 2015Lee's Pharmaceutical's first study: phase 1 study in HealthyNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT02477449 · 32 enrolled · China
- Jul 9, 2015Windtree Therapeutics's first study: phase 2 study in Acute Decompensated Heart FailureNew to Windtree TherapeuticsWindtree Therapeutics · NCT02617446 · 120 enrolled · China, Italy
- Mar 24, 2020Phase 2 study in Shock, CardiogenicWindtree Therapeutics · NCT04325035 · 90 enrolled · United States, Argentina, Italy and more
- Jul 26, 2023Phase 2 study in Shock, CardiogenicWindtree Therapeutics · NCT05975021 · 20 enrolled · United States, Argentina, Israel and more
- May 1, 2026Seismic Pharmaceuticals Operations's first study: phase 3 study in Shock, CardiogenicNew to Seismic Pharmaceuticals OperationsSeismic Pharmaceuticals Operations · NCT07583446 · 600 planned · Armenia
Ahead
- Dec 2028Primary completion: phase 3 study in Shock, CardiogenicSeismic Pharmaceuticals Operations · NCT07583446
TargetBeta
“Sodium/potassium-transporting ATPase inhibitor; Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator”ChEMBL 37, by rule
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07583446Shock, Cardiogenic · Armenia | 3 | Recruiting | Seismic Pharmaceuticals Operations | Dec 2028 | 600 |
| NCT05975021Shock, Cardiogenic · United States, Argentina, Israel and more | 2 | Active, not recruiting | Windtree Therapeutics | Jul 28, 2025 | 20 |
| NCT04325035Shock, Cardiogenic · United States, Argentina, Italy and more | 2 | Completed | Windtree Therapeutics | Sep 26, 2024 | 90 |
| NCT02617446Acute Decompensated Heart Failure · China, Italy | 2 | Completed | Windtree Therapeutics | Aug 14, 2018 | 120 |
| NCT02477449Healthy · China | 1 | Completed | Lee's Pharmaceutical | Oct 2015 | 32 |
| NCT00869115Heart Failure | 1 | Withdrawn | Debiopharm | 0 | |
| NCT00838253Heart Failure | 2 | Withdrawn | Debiopharm | 0 | |
| NCT00616161Heart Failure | 2 | Completed | sigma-tau i.f.r. | Jul 2007 | 120 |
How it is read
Names in the registry
- “Istaroxime”, 13 entries
- “istaroxime”, 2 entries
Conditions, from the studies’ own filings
- Heart Failure, 4 studies
- Shock, Cardiogenic, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.